跳至主要内容
临床试验/NCT02238795
NCT02238795已完成不适用

Sepsis-Associated Purpura Fulminans International Registry - Europe

Jena University Hospital3 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2016年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
3
主要终点
Mortality

研究概览

简要总结

Sepsis-associated Purpura fulminans (SAPF) is a rare life-threatening condition. It is characterized by multiple skin lesions which rapidly progress to necrosis and gangrene. SAPF is a manifestation of widespread clot formation in small blood vessels which emerges secondarily to severe bacterial and viral infections. The clinical presentation of SAPF is dominated by symptoms of severe sepsis and multiple organ failure which are further aggravated by the massive skin lesions.

At present, there are no evidence-based guidelines for the medical management of SAPF. With numerous therapeutic approaches in use, there are no consistent comparisons of their efficacy. Altered role of causal pathogens following the introduction of meningococcal and pneumococcal prophylactic vaccines also remains to be investigated.

The goal of the registry is comprehensive collection and evaluation of information concerning the epidemiology, morbidity, therapy and outcome of SAPF.

详细描述

Purpura fulminans is the clinical manifestation of disseminated thrombosis in dermal and systemic microcirculation. This rare disease is frequently associated with multiple organ failure and represents a life-threatening condition with mortality exceeding 50 %. In the vast proportion of cases, the condition has been shown to emerge secondary to acquired Protein C deficiency associated with severe sepsis, mostly of meningococcal or pneumococcal origin.

A consistent therapeutic approach to sepsis-associated Purpura fulminans (SAPF) has not been established yet. With exaggerated pro-coagulant activity being confirmed as the key pathogenic aspect, several treatment modalities aiming at the balance restoration in the coagulation cascade have been considered.

SAPF causality might have been substantially altered in the wake of widespread meningococcal and pneumococcal vaccination. There are neither evidence-based treatment guidelines nor comparative evaluation of the efficacy of different therapeutic approaches.

The present registry aims at a) large-scale data accumulation and comprehensive evaluation of the incidence, causality and current treatment strategies of SAPF, b) comparative assessment of treatment strategies including or not including protein C supplementation c) identification of patient subgroups of particular eligibility for Protein C treatment, as judged by established criteria of disease severity assessment, d) feedback of aggregated data to registry contributors, thus permitting quality management and standard updates, e) dissemination of data evaluation summaries and recommendations for the use of Protein C formulations in clinical routine, f) elaboration of a framework for SAPF treatment recommendations and guidelines.

The registry comprises prospective, multicentric open-label data collection on the current state of incidence and management of SAPF, regardless of the etiopathogenic background. It will include comprehensive records on diagnosis, morbidity and management of SAPF, supplied in the form of electronic case report forms (eCRFs) by the participating centers over a period of three years.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of sepsis and Purpura fulminans
  • Signed informed consent

排除标准

  • Premature neonates (below gestational age of 36 weeks)

结局指标

主要结局

Mortality

时间窗: during hospital stay (estimated up to 3 months)

All-cause in-hospital mortality

次要结局

  • Duration of ICU Stay(during ICU stay (estimated up to 3 months))
  • Hospital Stay(duration of hospital stay, up to 3 months)
  • Protein C(until day 7)
  • Extent and Severity of Purpura Fulminans Lesions(7 days)
  • Mean Total Sepsis-related Organ Failure Assessment (SOFA) Score(day 7)
  • Adverse Drug Reaction: Bleeding(during ICU stay)
  • Adverse Drug Reaction: Thrombotic Events(during ICU stay)
  • Adverse Drug Reactions: Visual Nerve Damage(during hospital stay (estimated up to 3 months))
  • Amputation(during ICU stay)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验